Infectious Disease · AntiviralRegulatory Approvalregulatorymid-term

ACTAVIS Mid Atlantic's Aciclovir ANDA074738 Receives AP Status

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/9/2026, 6:32:08 AM

Assessment confidence: 63% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of ACTAVIS's acyclovir ANDA074738 is significant as it enhances their competitive position in the antiviral market. Portfolio teams must evaluate the implications for existing acyclovir products, particularly in terms of market share and pricing strategies. Regulatory context from FDA (FDA AP — ACYCLOVIR (SUPPL)) supports the near-term read. Assessment grounded in 25 ranked evidence items (10 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market share and pricing strategies for acyclovir products. The strongest clinical anchor is Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders (ClinicalTrials.gov), moderate corpus alignment. In Infectious Disease · Antiviral, 8 regulatory and 6 competitive items passed relevance filtering for ACTAVIS MID ATLANTIC.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Elecsys IGRA TB Test Receives CE Mark for Tuberculosis Detection (Humanexa Signals) — mechanism alignment (io ); sponsor/company relevance (roche). Secondary pressure from [Ad hoc announcement pursuant to Art.. This approval may enhance ACTAVIS's position in the antiviral market, particularly against existing acyclovir products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — ACYCLOVIR (SUPPL) (FDA). Entity match (actavis mid atlantic); Regulatory pathway relevance (nda). The approval status indicates a successful regulatory review, but final approval and market launch timelines will need to be monitored closely.

Key Risks

Elevated medium regulatory exposure for ACTAVIS MID ATLANTIC could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

This approval could lead to increased competition in the acyclovir segment, potentially affecting pricing and market share for current players.
Portfolio teams should assess the impact of this approval on market share and pricing strategies for acyclovir products.

What Would Change This Assessment

This becomes more urgent if Monitor for the final approval and market launch timelines for ANDA074738.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — ACYCLOVIR (SUPPL)
FDAhigh relevance
Entity match (actavis mid atlantic); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — RISPERIDONE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GABAPENTIN (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FIORICET W/ CODEINE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ELTROMBOPAG OLAMINE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Remote Dynamic Cycling for the Customized Off-site Rehab in Parkinson's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's Elecsys IGRA TB Test Receives CE Mark for Tuberculosis Detection
Humanexa Signalshigh relevance
Mechanism alignment (IO ); Sponsor/company relevance (Roche)
[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)
FDA Approves Veklury as First Treatment for COVID-19
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Emergency Use Authorization for Remdesivir in Severe COVID-19 Cases
Humanexa Signalsmedium relevance
Moderate corpus alignment

RNA polymerase II phosphorylation dynamics: from molecular mechanisms to human disease.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Purinergic activity of circulating extracellular vesicles associates with disease progression in melanoma.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immune response to rotavirus vaccines in low- and middle-income countries: Challenges and perspectives.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Gut microbial metabolism of Flutamide attenuates its therapeutic efficacy against prostate cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

ACTAVIS MID ATLANTIC
acyclovir

Commercial impact

medium

This approval could lead to increased competition in the acyclovir segment, potentially affecting pricing and market share for current players.

Regulatory impact

medium

The approval status indicates a successful regulatory review, but final approval and market launch timelines will need to be monitored closely.

What to watch

Monitor for the final approval and market launch timelines for ANDA074738.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.